CASI Pharmaceuticals (FRA:ENM) Total Liabilities : €39.14 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Total Liabilities?

CASI Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €39.14 Mil.

CASI Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2023 (€22.30 Mil) to Dec. 2023 (€46.86 Mil) but then declined from Dec. 2023 (€46.86 Mil) to Mar. 2024 (€39.14 Mil).

CASI Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€26.85 Mil) to Dec. 2022 (€27.66 Mil) and increased from Dec. 2022 (€27.66 Mil) to Dec. 2023 (€46.86 Mil).

CASI Pharmaceuticals Total Liabilities Historical Data

The historical data trend for CASI Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Total Liabilities Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

8.07

19.86

26.85

27.66

46.86

CASI Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															24.45	22.18	22.30	46.86	39.14

CASI Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CASI Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.338	+	(18.809	+	12.714
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	46.86

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	69.021	-	22.159
	=	46.86

CASI Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7.86	+	(17.099	+	14.181
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	39.14

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	53.37	-	14.23
	=	39.14

CASI Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines